Globus Medical, Inc. (GMED) EPS Estimated At $0.40 on February, 20

Globus Medical, Inc. (NYSE:GMED) Corporate Logo
During 2018 Q3 the big money sentiment increased to 1.23. That’s change of 0.05, from 2018Q2’s 1.18. 22 investors sold all, 88 reduced holdings as Globus Medical, Inc. ratio improved. 81 increased positions while 54 funds acquired positions. Funds hold 60.77 million shares thus 1.87% more from 2018Q2’s 59.66 million shares.
Com Bank & Trust reported 19,945 shs or 0.01% of all its holdings. 145,300 are held by Tiaa Cref Investment Mngmt Ltd Liability. Oregon Pub Employees Retirement Fund has invested 0.02% of its capital in Globus Medical, Inc. (NYSE:GMED). Ameritas Invest, a Nebraska-based fund reported 41,450 shs. Ny State Teachers Retirement Sys holds 0% or 10,400 shs. First Hawaiian Bancorp, a Hawaii-based fund reported 370 shs. Paradigm Cap Mgmt reported 732,200 shs stake. Dupont Management accumulated 51,551 shs. Texas Permanent School Fund has 46,113 shs for 0.04% of their capital. 182,635 were accumulated by Gotham Asset Mngmt Limited Com. Profund Advsrs Limited Com holds 12,039 shs. 100 were reported by Macquarie Group Incorporated Limited. Retirement Of Alabama holds 94,711 shs. 567,148 are owned by Wells Fargo And Com Mn. Public Sector Pension Invest Board, Quebec – Canada-based fund reported 45,000 shs.

Globus Medical, Inc. (NYSE:GMED)’s earnings report is expected on February, 20., as reported by Faxor. The EPS diference is $0.02 or 5.26 % up from last years number. Previous year: $0.38; Analysts forcast: $0.40. If EPS of $0.40 is announced the profit of GMED could be $39.38M giving it 28.93 P/E. Last quarter $0.39 EPS was reported. Analysts sees 2.56 % EPS growth this quarter. GMED is reaching $46.29 during the last trading session, after decreased 0.58%.Currently Globus Medical, Inc. is uptrending after 15.76% change in last February 14, 2018. GMED has also 428,590 shares volume. The stock outperformed the S&P 500 by 15.76%.

Globus Medical, Inc. (NYSE:GMED) Ratings Coverage

Total analysts of 3 have positions in Globus Medical (NYSE:GMED) as follows: 1 rated it a “Buy”, 0 with “Sell” and 2 with “Hold”. The positive are 33%. Since September 25, 2018 according to StockzIntelligence Inc Globus Medical has 4 analyst reports. On Tuesday, September 25 the firm has “Overweight” rating given by Morgan Stanley. On Wednesday, January 2 the firm has “Equal-Weight” rating by Morgan Stanley given.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders.The firm is valued at $4.56 billion. The firm offers products that address an array of spinal pathologies, anatomies, and surgical approaches.32.3 is the P/E ratio. It provides fusion products that are used in cervical, thoracolumbar, sacral, and interbody/corpectomy fusion procedures to treat degenerative, deformity, tumor, and trauma conditions.

For more Globus Medical, Inc. (NYSE:GMED) news published briefly go to: Globenewswire.com, Investorplace.com, Seekingalpha.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Globus Medical’s SECUREĀ®C Cervical Artificial Disc Receives Expanded Insurance Coverage – GlobeNewswire” published on January 24, 2019, “7 Stocks to Buy That Lost 20% Over Past 90 Days – Investorplace.com” on January 23, 2019, “Device makers in the green after BSX and EW settle patent fights – Seeking Alpha” with a publish date: January 15, 2019, “Globus Medical Reports First Quarter 2018 Results NYSE:GMED – GlobeNewswire” and the last “Globus Medical Reports Second Quarter 2018 Results NYSE:GMED – GlobeNewswire” with publication date: August 01, 2018.

Globus Medical, Inc. (NYSE:GMED) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.